Dr. Lal Path Labs Ltd.

rs 31

mpany 70+ years of experience in the field of diagnostics 100 Mn patients serviced in last 5 years 31 NABL accredited Labs; 2 CAP accredited Labs Largest* diagnostics chain in the country with PAN

20%

asis of revenue and presence Note: Figures includes Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl.

120%

s Suburban Diagnostics w.e.f. 12th November 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically sp

44%

ember 2021 20% 3 Year Revenue CAGR 20% 3-Year PAT CAGR 120% Equity Dividend for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 419 crore (Net

Rs. 419 crore

for FY 21-22 ~44% ROCE Excl. Cash & Investments 277 Labs; Geographically spread out network Rs. 419 crore (Net) Cash & Investments as on 30th September, 22 4,731 Patient Service Centres (PSC’s) 5,113

INR 534

31, 2022 * Includes 38 Labs, 177 PSC’s and 983 PUP’s of Suburban Diagnostics 5 Q2 FY23 Snapshot INR 534 Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin I

7%

of Suburban Diagnostics 5 Q2 FY23 Snapshot INR 534 Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr C

9%

burban Diagnostics 5 Q2 FY23 Snapshot INR 534 Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr Covid

INR 150

an Diagnostics 5 Q2 FY23 Snapshot INR 534 Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr Covid Revenue 1

28%

hot INR 534 Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr Covid Revenue 19 MN Non-Covid Samples -6

INR 514

Cr Total Revenue 7 MN Non-Covid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr Covid Revenue 19 MN Non-Covid Samples -61% +12% INR 86

15%

vid Patients +7% +9% INR 150 Cr Normalised EBITDA* 28% Margin INR 514 Cr Non Covid Revenue +15% INR 20 Cr Covid Revenue 19 MN Non-Covid Samples -61% +12% INR 86 Cr Normalised PAT** 16% M